Study of Cognitive Changes and Biomarkers in Adults Undergoing Transurethral Resection of Bladder Tumor under General Anesthesia

What this Trial Is About

Bladder tumor is a common cancer worldwide, especially affecting an elderly population with multiple health issues. Researchers are studying the connection between perioperative cognitive dysfunction and circulating biomarkers of neurological damage in patients undergoing transurethral resection of bladder tumor TURM under general anesthesia. This observational study focuses on identifying risk factors such as neuroinflammation, oxidative stress, and frailty that may influence cognitive decline after surgery in this vulnerable group. Participants in this study are adult patients aged 18 to 80 years scheduled for elective TURM surgery. The study will assess cognitive function using the Mini-Mental State Examination MMSE and Montreal Cognitive Assessment MoCA before and after surgery. Muscle strength will be measured with a hand grip test, and blood samples will be collected to measure organic function markers and circulating neuroinflammatory indicators such as S100B, neuron-specific enolase, IL4, and IL6 at multiple time points during the perioperative period. During the study, participants will undergo cognitive tests at baseline, 24 hours, and 48 hours after surgery, along with blood tests at baseline, 2 hours, and 24 hours post-surgery. Researchers will also assess clinical frailty and muscle strength to explore their relationship with cognitive changes. This comprehensive evaluation aims to better understand factors affecting postoperative cognitive outcomes, with safety monitoring continuing through the surgical and early recovery phases.

Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor